Prognostic impact of home oxygen therapy on patients with resected non-small-cell lung cancer with interstitial lung disease

Surgery Today ◽  
2021 ◽  
Author(s):  
Keigo Sekihara ◽  
Keiju Aokage ◽  
Takashi Hiyama ◽  
Hiroaki Oiwa ◽  
Tomohiro Miyoshi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Interstitial Lung Disease ◽  
Small Cell Lung Cancer ◽  
Lung Disease ◽  
Cell Lung Cancer ◽  
Oxygen Therapy ◽  
Small Cell ◽  
Prognostic Impact ◽  
Small Cell Lung ◽  
Home Oxygen Therapy

scholarly journals Safety and efficacy of carboplatin plus nab-paclitaxel for treating advanced non-small-cell lung cancer with interstitial lung disease

2017 ◽  
Vol 7 (4) ◽  
pp. 604-608 ◽  
Author(s):  
Hideyuki Niwa ◽  
Yoshiro Nakahara ◽  
Masanori Yokoba ◽  
Hisashi Mitsufuji ◽  
Jiichiro Sasaki ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Interstitial Lung Disease ◽  
Small Cell Lung Cancer ◽  
Lung Disease ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Safety And Efficacy

scholarly journals Pembrolizumab for Previously Untreated Patients with Advanced Non-small-cell Lung Cancer and Preexisting Interstitial Lung Disease

2020 ◽  
Vol 59 (16) ◽  
pp. 1939-1945 ◽  
Author(s):  
Tetsuo Fujita ◽  
Tsuguko Kuroki ◽  
Nami Hayama ◽  
Yuka Shiraishi ◽  
Hiroyuki Amano ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Interstitial Lung Disease ◽  
Small Cell Lung Cancer ◽  
Lung Disease ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals Interstitial Lung Disease Induced by Crizotinib in Non-Small-Cell Lung Cancer

2019 ◽  
Vol 32 (3) ◽  
pp. 236 ◽  
Author(s):  
Andreia Tereso ◽  
Luís Carreto ◽  
Manuela Baptista ◽  
Maria Amélia Almeida
Keyword(s):  
Lung Cancer ◽  
Interstitial Lung Disease ◽  
Tyrosine Kinase ◽  
Small Cell Lung Cancer ◽  
Lung Disease ◽  
Tyrosine Kinase Inhibitors ◽  
Cell Lung Cancer ◽  
Kinase Inhibitors ◽  
Small Cell ◽  
Small Cell Lung

The treatment of advanced non-small-cell lung cancer shifted with the development of molecular-targeted therapies, like the tyrosine kinase inhibitors. One example of tyrosine kinase inhibitors is crizotinib, an anaplastic lymphoma tyrosine kinase inhibitor, which targets an echinoderm microtubule-associated protein-like-4-anaplastic lymphoma kinase gene fusion. This mutation is found in only 2% to 7% of non-small-cell lung cancer cases. Although these new therapies have shown promising results, the occurrence of interstitial lung disease as a side effect could be problematic. As the diagnosis of drug-related-interstitial lung disease is difficult to make, computed tomography is an important diagnostic tool. The recognition of computed tomography manifestations of tyrosine kinase inhibitors -induced interstitial lung disease is the key for an early recognition and management of this pulmonary toxicity. We aim to raise awareness of tyrosine kinase inhibitors-induced interstitial lung disease, by reporting the first case of a Portuguese patient treated with crizotinib for non-small-cell lung cancer who developed drug-induced interstitial lung disease.

ILD-NSCLC-GAP index scoring and staging system for patients with non-small cell lung cancer and interstitial lung disease

Lung Cancer ◽  
2018 ◽  
Vol 121 ◽  
pp. 48-53 ◽  
Author(s):  
Haruki Kobayashi ◽  
Tateaki Naito ◽  
Katsuhiro Omae ◽  
Shota Omori ◽  
Kazuhisa Nakashima ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Interstitial Lung Disease ◽  
Small Cell Lung Cancer ◽  
Lung Disease ◽  
Cell Lung Cancer ◽  
Staging System ◽  
Small Cell ◽  
Small Cell Lung
Sign in / Sign up

Export Citation Format

Share Document